Bayer will present new data from its continued research on Stivarga® (regorafenib) in metastatic colorectal cancer (mCRC) and metastatic biliary tract cancers, and Nexavar® (sorafenib) in advanced liver cancer, at the 2019 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on January 17-19 in San Francisco.
Among the research presented will be the final analysis from the prospective, observational CORRELATE study, which analyzed the overall survival of over 900 patients with mCRC in relation to the location of their primary tumor. Additionally, results from the REACHIN trial exploring the efficacy of regorafenib in patients with locally advanced (non-resectable) and metastatic biliary tract tumors that progress after chemotherapy will be presented. Findings from additional studies of regorafenib in mCRC will also be presented, including results from the Phase II LCCC1029 trial investigating second line FOLFIRI with regorafenib or placebo in mCRC.
Further presentations will highlight results from ongoing trials investigating outcomes of tyrosine kinase inhibitors used after, or in combination with immunotherapy, in advanced hepatocellular carcinoma patients.
Notable regorafenib and sorafenib studies at the ASCO GI 2019 Cancers Symposium include:
Regorafenib
- Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study
- Abstract: 539, Poster Session C; January 19, 07:00 – 7:55 am and 12:15 – 1:45 pm (PST); Board F2
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (non resectable) and metastatic biliary tumors: a randomized double-blinded placebo-controlled Phase II trial
- Abstract: 345, Poster Session B; January 18, 11:30 am – 1:00 pm and 5:30 – 6:30 pm (PST); Board J3
- Association of consensus molecular subtypes (CMS) with progression free survival (PFS) and overall survival (OS) with 2nd-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC)
- Abstract: 597, Poster Session C; January 19, 07:00 – 7:55 am and 12:15 – 1:45 pm (PST); Board H20
- Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029
- Abstract: 587, Poster Session C; January 19, 07:00 – 7:55 am and 12:15 – 1:45 pm (PST); Board H10
- Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603
- Abstract: 509, Poster Session C; January 19, 07:00 – 7:55 am and 12:15 – 1:45 pm (PST); Board D12
Sorafenib
- Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients
- Abstract: 361, Poster Session B; January 18, 11:30 am – 1:00 pm and 5:30 – 6:30 pm (PST); Board K1
- Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO)
- Abstract: TPS464, Poster Session B; January 18, 11:30 am – 1:00 pm and 5:30 – 6:30 pm (PST); Board Q3
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.